


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the January 2012 NCCN Trends™ Survey, which focused on Breast Cancer. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS

Distribution of Respondent Types (n = 1,744)†




†Note: Percentages may not total 100 because of rounding


© National Comprehensive Cancer Network, Inc. 2012 All Rights Reserved. For Personal Use Only.

This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.

Q1. Do you treat patients with breast cancer? (n=1754)




Q2. Which assay do you use most frequently in your practice for assessing the risk of breast cancer recurrence? (n = 1,195)



Q2. Which assay do you use most frequently in your practice for assessing the risk of breast cancer recurrence?


By Geography†



†Note: Percentages may not total 100 because of rounding


Q2. Which assay do you use most frequently in your practice for assessing the risk of breast cancer recurrence?

By Practice Size



Q2. Which assay do you use most frequently in your practice for assessing the risk of breast cancer recurrence?


By Practice Setting†



†Note: Percentages may not total 100 because of rounding


Q2. Which assay do you use most frequently in your practice for assessing the risk of breast cancer recurrence?

By Specialty†




†Note: Percentages may not total 100 because of rounding

Q3. Would having the results of an assay that determines the risk of breast cancer recurrence within 48 hours reduce anxiety for your patients? (n = 1,127)



Q3. Would having the results of an assay that determines the risk of breast cancer recurrence within 48 hours reduce anxiety for your patients?


By Geography†



†Note: Percentages may not total 100 because of rounding


Q3. Would having the results of an assay that determines the risk of breast cancer recurrence within 48 hours reduce anxiety for your patients?

By Practice Size




Q3. Would having the results of an assay that determines the risk of breast cancer recurrence within 48 hours reduce anxiety for your patients?

By Practice Setting




Q3. Would having the results of an assay that determines the risk of breast cancer recurrence within 48 hours reduce anxiety for your patients?

By Specialty




Q4. Are you aware of the inherent heterogeneity issues in breast cancer and how some PCR (polymerase chain reaction)-based assays that determine the risk of breast cancer recurrence may be confounded by proliferative stromal tissue, inflammatory cells, or benign tissue? (n=1,117)




Q4. Are you aware of the inherent heterogeneity issues in breast cancer and how some PCR (polymerase chain reaction)-based assays that determine the risk of breast cancer recurrence may be confounded by proliferative stromal tissue, inflammatory cells, or benign tissue?

By Geography




Q4. Are you aware of the inherent heterogeneity issues in breast cancer and how some PCR (polymerase chain reaction)-based assays that determine the risk of breast cancer recurrence may be confounded by proliferative stromal tissue, inflammatory cells, or benign tissue?

By Practice Size




Q4. Are you aware of the inherent heterogeneity issues in breast cancer and how some PCR (polymerase chain reaction)-based assays that determine the risk of breast cancer recurrence may be confounded by proliferative stromal tissue, inflammatory cells, or benign tissue?

By Practice Setting




Q4. Are you aware of the inherent heterogeneity issues in breast cancer and how some PCR (polymerase chain reaction)-based assays that determine the risk of breast cancer recurrence may be confounded by proliferative stromal tissue, inflammatory cells, or benign tissue?

By Specialty




Q5. What is your level of interest in the following to learn more about assays used to determine the risk of breast cancer recurrence? (Check all that apply)†



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in the following to learn more about assays used to determine the risk of breast cancer recurrence? (Check all that apply)


By Geography†



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in the following to learn more about assays used to determine the risk of breast cancer recurrence? (Check all that apply)


By Practice Size †



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in the following to learn more about assays used to determine the risk of breast cancer recurrence? (Check all that apply)


By Practice Setting†



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in the following to learn more about assays used to determine the risk of breast cancer recurrence? (Check all that apply)

By Specialty†



†Note: Percentages may not total 100 because of rounding

NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.com - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.